Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial.
Gridelli C, Gallo C, Morabito A, Iaffaioli RV, Favaretto A, Isa L, Barbera S, Gamucci T, Ceribelli A, Filipazzi V, Maione P, Rossi A, Barletta E, Signoriello S, De Maio E, Piccirillo MC, Di Maio M, Rocco G, Vecchione A, Perrone F; G-STEP Investigators. Gridelli C, et al. Among authors: vecchione a. J Thorac Oncol. 2012 Jan;7(1):233-42. doi: 10.1097/JTO.0b013e318233d6c2. J Thorac Oncol. 2012. PMID: 22031232 Free article. Clinical Trial.
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification.
Mazzotta M, Filetti M, Rossi A, Roberto M, Occhipinti M, Pernazza A, Di Napoli A, Scarpino S, Vecchione A, Giusti R, Marchetti P. Mazzotta M, et al. Among authors: vecchione a. Ann Oncol. 2020 Mar;31(3):440-441. doi: 10.1016/j.annonc.2019.11.016. Epub 2019 Dec 9. Ann Oncol. 2020. PMID: 32067689 Free article. No abstract available.
Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.
Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, Chiou YY, Huang GT, Cai J, Abdullah BJJ, Lee JS, Lee JY, Choi JY, Gopez-Cervantes J, Sherman M, Finn RS, Omata M, O'Neal M, Makris L, Borys N, Poon R, Lencioni R. Tak WY, et al. Among authors: vecchione a. Clin Cancer Res. 2018 Jan 1;24(1):73-83. doi: 10.1158/1078-0432.CCR-16-2433. Epub 2017 Oct 10. Clin Cancer Res. 2018. PMID: 29018051 Clinical Trial.
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, Rasio D, Vecchione A, Di Palma M. Alimonti A, et al. Among authors: vecchione a. Cancer Treat Rev. 2004 Oct;30(6):555-62. doi: 10.1016/j.ctrv.2004.05.002. Cancer Treat Rev. 2004. PMID: 15325035 Review.
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G, Giannetta L, Ucci G, De Signoribus G, Vecchione A, Pinotti G, Puglisi F, Contillo A, Pezzella G, Orecchia S, Beccaglia P; OBI/EPO-ITA-01/1 study group. Cartenì G, et al. Among authors: vecchione a. Support Care Cancer. 2007 Sep;15(9):1057-66. doi: 10.1007/s00520-007-0220-4. Epub 2007 Apr 13. Support Care Cancer. 2007. PMID: 17431689 Clinical Trial.
435 results